A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with ...

Researchers found that the Wnt5a protein, secreted by inflammatory fibroblasts within cancerous tumors, inhibits angiogenesis and consequently promotes hypoxia within tumors. Hypoxic conditions help ...

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...

(AP Photo/JoNel Aleccia) FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual ...

Credit: Getty Images Until semaglutide, weight loss of 15% to avoid obesity-related complications was only achieved through bariatric surgery. In clinical trials, semaglutide proved to be superior to ...

Research backs up this frustrating fact. Diet and exercise tend to benefit men much more than women when it comes to losing weight. That’s why the results of recent clinical trials were ...

Hi, Carolyn: After spending my entire adult life fighting my weight and being medically classified as overweight, then obese, I have finally found some success with the new GLP-1 weight loss drugs.

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...

Share on Pinterest A Wegovy weight loss pill from Novo Nordisk is forthcoming, providing an alternative to injectable GLP-1 drugs. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images Federal ...